<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114697</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00059784</org_study_id>
    <nct_id>NCT02114697</nct_id>
  </id_info>
  <brief_title>Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging</brief_title>
  <official_title>Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess a slimy substance that settles/deposits along blood
      vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium
      or both. Plaque deposition narrows the vessels. This leads to decreased blood flow to various
      parts of body. Blood vessels include vessels that supply to heart (coronary), vessels to
      brain (carotid), vessels to kidneys (renal) and vessels to legs (femoral). Decreased blood
      flow causes symptoms such as brain stroke, heart attack, leg pain. Similarly individuals at
      risk of cardiovascular disease can have certain markers elevated in their blood that can be
      measured by simple blood tests.

      High or increased plaque deposition is seen in neck vessels of cancer patients who received
      radiation to chest or head and neck as part of their cancer treatment. Cancer survivors are
      at increased risk of plaque development and are therefore called high-risk population.
      Exercise +/- fat lowering medicine can potentially decrease plaque deposition and statins are
      one of the several fat lowering medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) and cancer are the leading causes of suffering and death amongst
      the American population. While an ever-increasing number of cancer survivors have a favorable
      outcome due to advances in cancer treatment; cancer survivors remain at high risk of
      developing CVD at an early age. There is scant information available on the pathogenic
      process that contributes to cardiovascular threat amongst cancer survivors and little is
      known about the interventions, which may interrupt or decrease the risk of CVD in this
      population. Importantly, early-subclinical markers may substantially precede clinical
      markers.

      The objective of this project is to accurately determine the constituents and characteristics
      of atherosclerotic plaques in carotid arteries by magnetic resonance imaging (MRI) techniques
      in cancer survivors; at different data intervals: before and after administration of
      treatment (medical and life style modification) and then correlate contrast agent dynamics
      with serum markers of inflammation and other tests of cardiac or vascular dysfunction, where
      available.

      The proposed study involves 100 asymptomatic patients who received prior chest or head and
      neck radiation therapy (HNXRT) as part of cancer treatment. MRI data (direct assessment of
      atherosclerosis) would be correlated with indirect measures of atherosclerosis (blood
      surrogate markers &amp; metabolomics).

      The investigators intend to conduct an initial baseline MRI, blood tests (to correlate with
      surrogate markers of inflammation) and other tests whenever available of cardiac or vascular
      dysfunction. This cohort will be followed up with medication and/or life style modification
      regimen for a period of initially18 months and subsequently at 36 months. A repeat of all
      baseline studies (MRI and blood tests) would be performed as part of the 18 and 36-month
      follow-up. The plaque characteristics found at MRI will be correlated with results of blood
      tests (baseline, 18 and 36 months) and changes in one or both will be the expected end point
      of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiovascular disease confirmed by MRI of carotid arteries</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Plaque features including plaque volume and complexity will act as surrogate measures for progression of cardiovascular disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cardiovascular disease confirmed by MRI of carotid arteries</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>Plaque features including plaque volume and complexity will act as surrogate measures for progression of cardiovascular disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Lifesyle modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg once a day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg - drug administered orally, once a day, for the duration of the trial, which is 3 years (to be discontinued on account of unacceptable adverse effects)</description>
    <arm_group_label>Rosuvastatin 20 mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.</description>
    <arm_group_label>Lifesyle modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 22 and above with prior head and neck or chest irradiation

          -  Six months or more post head and neck irradiation

          -  Documented subclinical cardiovascular disease (inflammatory markers in the serum)

          -  Pre-existing plaques [detected by ultrasound, CT or MRI]

          -  Asymptomatic major arterial stenosis

          -  Not being considered for arterial surgery or endovascular treatment.

        Exclusion Criteria:

          -  Recurrence of cancer (with or without treatment)

          -  Planned surgical or endovascular intervention for revascularization of carotid
             arteries at the time of enrollment

          -  Renal failure

          -  eGFR &lt; 45 (calculation based on serum creatinine levels, race, age and gender)

          -  Medically unstable or hematologic, renal, or hepatic dysfunction

          -  Non-atherosclerotic arterial stenosis (dissection)

          -  Presence of stents or external clips that can cause artifacts impairing accurate
             interpretation of MRI data

          -  Contraindications to MRI: cardiac pacemaker, metal implants, metal in eyes, pregnant
             or nursing women, claustrophobia, allergy to MRI contrast

          -  Physical or mental impairment that would limit the patient's ability to comply with
             the medical instructions or study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Oshinski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ota H, Yu W, Underhill HR, Oikawa M, Dong L, Zhao X, Polissar NL, Neradilek B, Gao T, Zhang Z, Yan Z, Guo M, Zhang Z, Hatsukami TS, Yuan C. Hemorrhage and large lipid-rich necrotic cores are independently associated with thin or ruptured fibrous caps: an in vivo 3T MRI study. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1696-701. doi: 10.1161/ATVBAHA.109.192179. Epub 2009 Jul 16.</citation>
    <PMID>19608971</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002 Dec;15(6):439-46. Review.</citation>
    <PMID>12476646</PMID>
  </reference>
  <reference>
    <citation>Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010 Apr 6;152(7):409-17, W131-8. doi: 10.7326/0003-4819-152-7-201004060-00005.</citation>
    <PMID>20368646</PMID>
  </reference>
  <reference>
    <citation>Dorresteijn LD, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB, van Leeuwen FE, Bartelink H. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002 Jan 1;20(1):282-8.</citation>
    <PMID>11773180</PMID>
  </reference>
  <reference>
    <citation>Jordan LC, Duffner PK. Early-onset stroke and cerebrovascular disease in adult survivors of childhood cancer. Neurology. 2009 Dec 1;73(22):1816-7. doi: 10.1212/WNL.0b013e3181c33b10. Epub 2009 Oct 21.</citation>
    <PMID>19846829</PMID>
  </reference>
  <reference>
    <citation>Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, Leisenring WM, Meacham LR, Mertens AC, Mulrooney DA, Oeffinger KC, Packer RJ, Robison LL, Sklar CA. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009 May 10;27(14):2339-55. doi: 10.1200/JCO.2008.21.1953. Epub 2009 Apr 13. Review.</citation>
    <PMID>19364955</PMID>
  </reference>
  <reference>
    <citation>Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, Smithson WA, Robison LL. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001 Jul 1;19(13):3163-72.</citation>
    <PMID>11432882</PMID>
  </reference>
  <reference>
    <citation>Haynes JC, Machtay M, Weber RS, Weinstein GS, Chalian AA, Rosenthal DI. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. Laryngoscope. 2002 Oct;112(10):1883-7.</citation>
    <PMID>12368635</PMID>
  </reference>
  <reference>
    <citation>Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, Robison LL, Packer RJ, Oeffinger KC. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006 Nov 20;24(33):5277-82. Epub 2006 Nov 6.</citation>
    <PMID>17088567</PMID>
  </reference>
  <reference>
    <citation>Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006 Apr 1;107(7):2912-9. Epub 2005 Dec 8.</citation>
    <PMID>16339404</PMID>
  </reference>
  <reference>
    <citation>Steele SR, Martin MJ, Mullenix PS, Crawford JV, Cuadrado DS, Andersen CA. Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer. Am J Surg. 2004 May;187(5):594-8.</citation>
    <PMID>15135672</PMID>
  </reference>
  <reference>
    <citation>Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation. 2003 Apr 29;107(16):2072-5. Review.</citation>
    <PMID>12719287</PMID>
  </reference>
  <reference>
    <citation>Hatsukami TS, Ross R, Polissar NL, Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation. 2000 Aug 29;102(9):959-64.</citation>
    <PMID>10961958</PMID>
  </reference>
  <reference>
    <citation>MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1333-42. Epub 2003 Jun 12. Review.</citation>
    <PMID>12805071</PMID>
  </reference>
  <reference>
    <citation>Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001 Feb 20;103(7):926-33.</citation>
    <PMID>11181465</PMID>
  </reference>
  <reference>
    <citation>Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996 Oct 15;94(8):2013-20. Review.</citation>
    <PMID>8873680</PMID>
  </reference>
  <reference>
    <citation>Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV, Gold HK. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004 Dec;90(12):1385-91. Review.</citation>
    <PMID>15547008</PMID>
  </reference>
  <reference>
    <citation>Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. Review.</citation>
    <PMID>15843671</PMID>
  </reference>
  <reference>
    <citation>Krams R, Segers D, Mousavi Gourabi B, Maat W, Cheng C, van Pelt C, van Damme LC, de Feyter P, van der Steen T, de Korte CL, Serruys PW. Inflammation and atherosclerosis: mechanisms underlying vulnerable plaque. J Interv Cardiol. 2003 Apr;16(2):107-13.</citation>
    <PMID>12768913</PMID>
  </reference>
  <reference>
    <citation>Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19-26;420(6917):868-74. Review.</citation>
    <PMID>12490960</PMID>
  </reference>
  <reference>
    <citation>Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329. Review.</citation>
    <PMID>18039117</PMID>
  </reference>
  <reference>
    <citation>Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-43. Review.</citation>
    <PMID>11877368</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011 Jan 20;364(3):226-35. doi: 10.1056/NEJMoa1002358. Erratum in: N Engl J Med. 2011 Nov 24;365(21):2040.</citation>
    <PMID>21247313</PMID>
  </reference>
  <reference>
    <citation>Bengel FM. Vascular FDG uptake: further steps toward clinical acceptance. J Nucl Cardiol. 2008 Mar-Apr;15(2):154-6. doi: 10.1016/j.nuclcard.2008.01.010.</citation>
    <PMID>18371583</PMID>
  </reference>
  <reference>
    <citation>Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007 Jan;14(1):55-61. Review.</citation>
    <PMID>17133101</PMID>
  </reference>
  <reference>
    <citation>Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009 Nov;207(1):139-43. doi: 10.1016/j.atherosclerosis.2009.04.023. Epub 2009 Apr 24.</citation>
    <PMID>19467659</PMID>
  </reference>
  <reference>
    <citation>Fayad ZA, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann N Y Acad Sci. 2000 May;902:173-86. Review.</citation>
    <PMID>10865837</PMID>
  </reference>
  <reference>
    <citation>Mitsumori LM, Hatsukami TS, Ferguson MS, Kerwin WS, Cai J, Yuan C. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. J Magn Reson Imaging. 2003 Apr;17(4):410-20.</citation>
    <PMID>12655579</PMID>
  </reference>
  <reference>
    <citation>Yuan C, Mitsumori LM, Beach KW, Maravilla KR. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology. 2001 Nov;221(2):285-99. Review.</citation>
    <PMID>11687667</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</citation>
    <PMID>18997196</PMID>
  </reference>
  <reference>
    <citation>Courneya KS, Stevinson C, McNeely ML, Sellar CM, Friedenreich CM, Peddle-McIntyre CJ, Chua N, Reiman T. Effects of supervised exercise on motivational outcomes and longer-term behavior. Med Sci Sports Exerc. 2012 Mar;44(3):542-9. doi: 10.1249/MSS.0b013e3182301e06. Review.</citation>
    <PMID>21814149</PMID>
  </reference>
  <reference>
    <citation>Ahmed HM, Blaha MJ, Nasir K, Rivera JJ, Blumenthal RS. Effects of physical activity on cardiovascular disease. Am J Cardiol. 2012 Jan 15;109(2):288-95. doi: 10.1016/j.amjcard.2011.08.042. Epub 2011 Oct 18. Review.</citation>
    <PMID>22011559</PMID>
  </reference>
  <reference>
    <citation>Williams MA, Ades PA, Hamm LF, Keteyian SJ, LaFontaine TP, Roitman JL, Squires RW. Clinical evidence for a health benefit from cardiac rehabilitation: an update. Am Heart J. 2006 Nov;152(5):835-41. Review.</citation>
    <PMID>17070142</PMID>
  </reference>
  <reference>
    <citation>Pannu N, Tonelli M. Strategies to reduce the risk of contrast nephropathy: an evidence-based approach. Curr Opin Nephrol Hypertens. 2006 May;15(3):285-90. Review.</citation>
    <PMID>16609296</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>John Oshinski</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cancer survivorship, cardiovascular disease, stroke, TIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

